Harrington, R. A., Newby, L. K., Moliterno, D. J., Bhapkar, M., Armstrong, P. W., Simes, R. J., … Califf, R. M. (1997). Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: Evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 29(2), 3338–3338.

Harrington, R. A., L. K. Newby, D. J. Moliterno, M. Bhapkar, P. W. Armstrong, R. J. Simes, H. D. White, et al. “Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: Evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 29, no. 2 (February 1, 1997): 3338–3338.

Harrington RA, Newby LK, Moliterno DJ, Bhapkar M, Armstrong PW, Simes RJ, et al. Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: Evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 1997 Feb 1;29(2):3338–3338.

Harrington, R. A., et al. “Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: Evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 29, no. 2, ELSEVIER SCIENCE INC, Feb. 1997, pp. 3338–3338.

Harrington RA, Newby LK, Moliterno DJ, Bhapkar M, Armstrong PW, Simes RJ, White HD, VandeWerf F, Rames A, Topol EJ, Califf RM. Combining IIb/IIIa inhibition and heparin for acute coronary syndromes: Evidence of a gradient for bleeding hazard from the PARAGON randomized factorially designed trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 1997 Feb 1;29(2):3338–3338.